Increased glutathione utilization augments tumor cell proliferation in Waldenstrom Macroglobulinemia

WALDENSTROM ' S MACROGLOBULINEMIA 1453 Tumor Infiltration Bone Marrow Lymph Nodes

W ALDENSTROM’S macroglobulinemia (WM) accounts for approximately 2% of hematologic cancers and affects approximately 1,500 Americans each year. The disease is more frequent among older persons and there may be a genetic predisposition, as suggested by family clusters.”’ The original description of WM focused on bone marrow infiltration by plasmacytoid lymphocytes and a high level of circulating...

Novel agents in Waldenstrom Macroglobulinemia.

Waldenström's Macroglobulinemia (WM) is a B-cell disorder characterized by the infiltration of the bone marrow (BM) with lymphoplasmacytic cells, as well as detection of an IgM monoclonal gammopathy in the serum. WM is considered an incurable disease, with an overall median survival of only 5-6 years. The success of targeted therapy in multiple myeloma (MM) has led to the development and invest...

Waldenstrom macroglobulinemia: prognosis and management

Waldenstrom macroglobulinemia (WM) is a B-cell lymphoplasmacytic lymphoma characterized by monoclonal immunoglobulin M protein in the serum and infiltration of bone marrow with lymphoplasmacytic cells. Asymptomatic patients can be observed without therapy. First-line therapy should consist of the monoclonal anti-CD20 antibody, rituximab, given typically in combination with other agents. We pref...

Proteomic analysis of waldenstrom macroglobulinemia.

To better understand the molecular changes that occur in Waldenstrom macroglobulinemia (WM), we employed antibody-based protein microarrays to compare patterns of protein expression between untreated WM and normal bone marrow controls. Protein expression was defined as a >2-fold or 1.3-fold change in at least 67% of the tumor samples. Proteins up-regulated by >2-fold included Ras family protein...

Targeting NF-κB in Waldenstrom Macroglobulinemia